Crossmark

Development of 3D-Printed Mexiletine HCl Tablets: Exploring Formulation Strategies for High-Dose Loading

Published Online: 2025-10-13

Published Print: 2025-10

Authors

Kiamoeddin, Bushra

Ramcharan, Arwin

Hoummad, Anouar Ait

Ouwerkerk, Niels

Shokri, Fereshteh
License Information

Text and Data Mining valid from 2025-10-01

Version of Record valid from 2025-10-01
More Information

Article History

Received: 14 February 2025

Accepted: 2 September 2025

First Online: 13 October 2025

Declarations

:

: B.K., N.O., and F.S. were employees of Doser BV, the Netherlands during this research. Doser BV markets the DoseRx1. N.O. is a shareholder of Doser BV.

Document is current